Publication | Open Access

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Bone DiseaseZoledronic AcidBone HealthGlucocorticoid-induced OsteoporosisMedicineOsteoporosisBone MetabolismRheumatoid Arthritis